E. Wengel Kathryn's Insider Trades & SAST Disclosures
E. Wengel Kathryn's most recent trade in Johnson & Johnson was a trade of 30,841 Employee Stock Options (Right to Buy) done . Disclosure was reported to the exchange on Feb. 15, 2025.
Add Superstar Alert
Note
This is a custom search result for pattern E. Wengel Kathryn.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 30,841 | 30,841 | - | - | Employee Stock Options (Right to Buy) | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2025 | 1,903 | 1,903 | - | - | Restricted Share Units | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,837 | 96,673 (0%) | 0% | 0 | Common Stock | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 5,837 | 0 | - | - | Performance Share Units | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 2,393 | 94,280 (0%) | 0% | 156.7 | 375,007 | Common Stock |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,530 | 0 | - | - | Restricted Share Units | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 1,530 | 90,909 (0%) | 0% | 0 | Common Stock | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 651 | - | - | Restricted Share Units | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 651 | 89,602 (0%) | 0% | 0 | Common Stock | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 607 | 1,212 | - | - | Restricted Share Units | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 607 | 91,036 (0%) | 0% | 0 | Common Stock | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.71 per share. | 13 Feb 2025 | 480 | 90,429 (0%) | 0% | 156.7 | 75,221 | Common Stock |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 155.26 per share. | 13 Feb 2025 | 223 | 89,379 (0%) | 0% | 155.3 | 34,623 | Common Stock |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.15 per share. | 13 Feb 2025 | 200 | 90,836 (0%) | 0% | 156.2 | 31,230 | Common Stock |
|
Laboratory Corp. Of Americ...
|
Kathryn E. Wengel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 897 | 897 | - | - | Restricted Stock Unit | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2025 | 5,837 | 5,837 | - | - | Performance Share Units | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 100.06 per share. | 07 Feb 2025 | 32,762 | 115,027 (0%) | 0% | 100.1 | 3,278,166 | Common Stock |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Feb 2025 | 32,762 | 0 | - | - | Employee Stock Options (Right to Buy) | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 153.12 per share. | 07 Feb 2025 | 26,076 | 88,951 (0%) | 0% | 153.1 | 3,992,757 | Common Stock |
|
Laboratory Corp. Of Americ...
|
Kathryn E. Wengel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 944 | 0 | - | - | Restricted Stock Unit | |
|
Laboratory Corp. Of Americ...
|
Kathryn E. Wengel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2025 | 944 | 3,236 (0%) | 0% | - | Common Stock | |
|
Johnson & Johnson
|
E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 29,275 | 29,275 | - | - | Employee Stock Options (Right to Buy) | |
|
Johnson & Johnson
|
E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2024 | 1,819 | 1,819 | - | - | Restricted Share Units | |
|
Johnson & Johnson
|
E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 651 | 1,302 | - | - | Restricted Share Units | |
|
Johnson & Johnson
|
Wengel Kathryn E. | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2024 | 651 | 82,598 (0%) | 0% | 0 | Common Stock | |
|
Johnson & Johnson
|
E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.85 per share. | 13 Feb 2024 | 333 | 82,265 (0%) | 0% | 157.8 | 52,564 | Common Stock |
|
Johnson & Johnson
|
E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 11,826 | 87,026 (0%) | 0% | 0 | Common Stock | |
|
Johnson & Johnson
|
Kathryn Wengel E. | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 11,826 | 0 | - | - | Performance Share Units | |
|
Johnson & Johnson
|
E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 157.40 per share. | 12 Feb 2024 | 7,066 | 81,947 (0%) | 0% | 157.4 | 1,112,188 | Common Stock |
|
Johnson & Johnson
|
E. Kathryn Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 1,987 | 89,013 (0%) | 0% | 0 | Common Stock | |
|
Johnson & Johnson
|
Wengel Kathryn E. | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Feb 2024 | 35,638 | 0 | - | - | Employee Stock Options (Right to Buy) | |
|
Johnson & Johnson
|
E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 90.44 per share. | 09 Feb 2024 | 35,638 | 102,533 (0%) | 0% | 90.4 | 3,223,101 | Common Stock |
|
Johnson & Johnson
|
Wengel Kathryn E. | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.76 per share. | 09 Feb 2024 | 27,333 | 75,200 (0%) | 0% | 156.8 | 4,284,721 | Common Stock |
|
Johnson & Johnson
|
E. Wengel Kathryn | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,971 | 0 | - | - | Restricted Share Units | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2024 | 1,971 | 67,904 (0%) | 0% | 0 | Common Stock | |
|
Johnson & Johnson
|
Kathryn Wengel E. | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 156.33 per share. | 08 Feb 2024 | 1,009 | 66,895 (0%) | 0% | 156.3 | 157,737 | Common Stock |
|
Laboratory Corp. Of Americ...
|
E. Wengel Kathryn | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 947 | 944 | - | - | Restricted Stock Unit | |
|
Laboratory Corp. Of Americ...
|
E. Kathryn Wengel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2024 | 947 | 2,292 (0%) | 0% | - | Common Stock | |
|
Laboratory Corp. Of Americ...
|
Wengel Kathryn E. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2024 | 944 | 1,891 | - | - | Restricted Stock Unit | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Sale of securities on an exchange or to another person at price $ 160.00 per share. | 12 Jun 2023 | 12,465 | 65,933 (0%) | 0% | 160 | 1,994,400 | Common Stock |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 32,317 | 32,317 | - | - | Employee Stock Options (Right to Buy) | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 10,839 | 83,289 (0%) | 0% | 0 | Common Stock | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.01 per share. | 13 Feb 2023 | 4,891 | 78,398 (0%) | 0% | 162.0 | 792,391 | Common Stock |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 1,953 | 1,953 | - | - | Restricted Share Units | |
|
Laboratory Corp. Of Americ...
|
Kathryn E. Wengel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 742 | 1,345 (0%) | 0% | - | Common Stock | |
|
Laboratory Corp. Of Americ...
|
Kathryn E. Wengel | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Feb 2023 | 742 | 849 | - | - | Restricted Stock Unit | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,807 | 0 | - | - | Restricted Share Units | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Feb 2023 | 1,807 | 73,117 (0%) | 0% | 0 | Common Stock | |
|
Johnson & Johnson
|
Kathryn E. Wengel | EVP, Chief TO and Risk Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 162.08 per share. | 10 Feb 2023 | 667 | 72,450 (0%) | 0% | 162.1 | 108,107 | Common Stock |
|
Laboratory Corp. Of Americ...
|
Kathryn E. Wengel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 849 | 1,591 | - | - | Restricted Stock Unit |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges